Bioventus annual stock-based compensation
2019
2020
2021
2022
2023
2024
2025
Bioventus Stock-Based Compensation Growth & History (BVS)
Bioventus's stock-based compensation was $12.7M for fiscal 2025.
View full Bioventus company overviewBioventus annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $12.7M | −$601,000 | −4.53% |
| 2024 | 2024-12-31 | $13.3M | $10.6M | +387.66% |
| 2023 | 2023-12-31 | $2.7M | −$14.9M | −84.52% |
| 2022 | 2022-12-31 | $17.6M | −$2.3M | −11.38% |
| 2021 | 2021-12-31 | $19.8M | $19.8M | — |
| 2020 | 2020-12-31 | $0 | $0 | — |
| 2019 | 2019-12-31 | $0 | — | — |
Bioventus quarterly stock-based compensation
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q3.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-27 | $5.0M | $1.4M | +38.37% |
| Q1 2026 | 2026-03-28 | $3.3M | $850,000 | +35.21% |
| Q4 2025 | 2025-12-31 | $3.4M | $1.4M | +70.63% |
| Q3 2025 | 2025-09-27 | $3.2M | $685,000 | +27.50% |
| Q2 2025 | 2025-06-28 | $3.6M | −$2.1M | −36.94% |
| Q1 2025 | 2025-03-29 | $2.4M | −$576,000 | −19.26% |
| Q4 2024 | 2024-12-31 | $2.0M | — | — |
| Q3 2024 | 2024-09-28 | $2.5M | $658,000 | +35.90% |
| Q2 2024 | 2024-06-29 | $5.8M | — | — |
| Q1 2024 | 2024-03-30 | $3.0M | $1.1M | +61.97% |
| Q3 2023 | 2023-09-30 | $1.8M | −$2.8M | −60.56% |
| Q1 2023 | 2023-04-01 | $1.8M | −$3.0M | −62.24% |
| Q4 2022 | 2022-12-31 | $3.4M | −$2.7M | −43.82% |
| Q3 2022 | 2022-10-01 | $4.6M | −$1.3M | −21.72% |
| Q2 2022 | 2022-07-02 | $4.6M | −$1.2M | −21.13% |
| Q1 2022 | 2022-04-02 | $4.9M | $2.9M | +151.49% |
| Q4 2021 | 2021-12-31 | $6.1M | $6.1M | — |
| Q3 2021 | 2021-10-02 | $5.9M | $5.9M | — |
| Q2 2021 | 2021-07-03 | $5.9M | $5.9M | — |
| Q1 2021 | 2021-04-03 | $1.9M | $1.9M | — |
| Q4 2020 | 2020-12-31 | $0 | — | — |
| Q3 2020 | 2020-09-26 | $0 | — | — |
| Q2 2020 | 2020-06-27 | $0 | — | — |
| Q1 2020 | 2020-03-28 | $0 | — | — |
Bioventus stock-based compensation trends
Over the last five fiscal years, Bioventus's stock-based compensation increased from $0 to $12.7M, a change of $12.7M. The latest reported quarter, Q2 2026, shows $5.0M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Bioventus source filings ↗